


It's Time to See Your Future



The First Approved Treatment for Dry Age-Related Macular Degeneration (AMD)



EYE
CORRECTION
CENTRE



VALEDA[®]
Light Delivery System

Treatment With Valeda Can Help You See More Clearly Now and In the Future



Dry AMD is a degenerative disease and may result in vision loss



Dry AMD affects people in different ways

Your symptoms may be mild or you may have no symptoms for several years, if your dry AMD progresses, with time your ability to see clearly may change and you may experience vision loss.

Symptoms of dry AMD may include:

- Blurry or fuzzy vision
- Straight lines appear wavy or bent
- Reduced intensity/brightness of colors
- Trouble adapting to low light
- Loss of central vision, which is necessary for driving, reading, recognising faces and performing close-up work

Dry AMD can cause retinal cells to deteriorate in function or result in cell death leading to loss in vision. Valeda uses specific wavelengths of light to stimulate energy production within the cells resulting in improved cell health. Healthy retinal cells are important for good vision.

Early treatment can make a difference

There is no cure for dry AMD. Once retinal cells are lost, geographic atrophy scar remains, which leads to permanent vision loss. Early dry AMD diagnosis is important. Retinal health and vision loss management by your doctor can be started earlier with Valeda to improve vision and maintain benefits.

Don't delay. Ask your eye doctor if Valeda is right for you.



Indications for Use

The indicated use is for treatment of ocular damage and disease using photobiomodulation, including inhibition of inflammatory mediators, edema or drusen deposition, improvement of wound healing following ocular trauma or surgery, and increase in visual acuity and contrast sensitivity in patients with degenerative diseases such as dry age-related macular degeneration.

Tel: +44 (0) 1270 567477 | Email: lianne.stobo@eyecorrectioncentre.co.uk



www.eyecorrectioncentre.co.uk

©2025 LumiThera, Inc.
MKT-0134 enGB REV A